23856-21-5

Basic information

• Product Name: 1-BENZYL-1H-INDAZOL-5-YLAMINE
• Synonyms: 1-BENZYL-1H-INDAZOL-5-AMINE;1-BENZYL-1H-INDAZOL-5-YLAMINE;1-BENZYL-1H-INDAZOL-5-YLAMINE TRIHYDROCHLORIDE;1-benzyl-1h-indazol-5-amin;1-BENZYL-1H-INDAZOL-5-YLAMINE, 95+%;1-Benzyl-5-aMino-1H-Indazole;1-Benzylindazol-5-aMine;N-Benzyl-5-AMino-Indazole
• CAS NO: 23856-21-5
• Molecular Formula: C₁₄H₁₃N₃
• Molecular Weight: 223.27
• Mol File: 23856-21-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 147-148 °C
• Boiling Point: 441.6 °C at 760 mmHg
• Flash Point: 220.9 °C
• Appearance: /
• Density: 1.2 g/cm³
• Vapor Pressure: 5.36E-08mmHg at 25°C
• Refractive Index: 1.661
• PKA: 3.81±0.10(Predicted)
• CAS DataBase Reference: 1-BENZYL-1H-INDAZOL-5-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-1H-INDAZOL-5-YLAMINE(23856-21-5)
• EPA Substance Registry System: 1-BENZYL-1H-INDAZOL-5-YLAMINE(23856-21-5)

Safety Data

• Hazardous Substances Data: 23856-21-5(Hazardous Substances Data)

Usage

General Description

1-BENZYL-1H-INDAZOL-5-YLAMINE is a chemical compound with the molecular formula C17H15N3. It is a derivative of indazole and has a benzyl group attached to the nitrogen atom. 1-BENZYL-1H-INDAZOL-5-YLAMINE has potential use in pharmaceutical research and development, particularly in the synthesis of new drugs. It may also have applications in organic chemistry and materials science. Its specific properties and potential uses may vary depending on the context and the specific methods of its synthesis and handling.

InChI:InChI=1/C14H13N3/c15-13-6-7-14-12(8-13)9-16-17(14)10-11-4-2-1-3-5-11/h1-9H,10,15H2

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 5401-94-5 5-nitroindazole 
• 23856-20-4 5-nitro-1-(phenylmethyl)-1H-indazole 

Downstream Products

• 202272-67-1 (1-benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine 
• 202272-68-2 GW2974 
• 202198-17-2 (1-Benzyl-1H-indazol-5-yl)-(6-iodoquinazolin-4-yl)-amine 
• 659747-45-2 (1-benzyl-1H-indazol-5-yl)-[6-(1-ethoxy-vinyl)-quinazolin-4-yl]-amine 
• 659747-69-0 N-{4-[4-(1-benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]-thiazol-2-ylmethyl}-2,2,2-trifluoro-N-(2-methanesulfonyl-ethyl)-acetamide 
• 69628-00-8 3-benzyl-9-oxo-6,9-dihydro-3H-pyrazolo[4,3-f]quinoline-8-carboxylic acid 
• 69627-93-6 3-benzyl-9-oxo-6,9-dihydro-3H-pyrazolo[4,3-f]quinoline-8-carboxylic acid ethyl ester 
• 69628-06-4 3-benzyl-6-ethyl-9-oxo-6,9-dihydro-3H-pyrazolo[4,3-f]quinoline-8-carboxylic acid 
• 529510-06-3 (1-Benzyl-1H-indazol-5-yl)-[5-(2-methoxy-ethoxymethyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine 
• 1338250-40-0 C₃₀H₂₇N₇ 
• 1338250-44-4 C₂₉H₂₇N₇ 
• 1338250-48-8 C₂₇H₂₃N₇ 
• 202197-79-3 (1-benzyl-1H-indazol-5-yl)-(7-iodoquinazolin-4-yl)-amine hydrochloride 
• 202197-39-5 (1-benzyl-1H-indazol-5-yl)-(6-bromoquinazolin-4-yl)-amine 

Relevant articles and documents

Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach

Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting Her2 which can be used in clinical routine are lacking, and therefore, the development of novel inhibitors was undertaken. In this study, the well-established pyrrolopyrimidine scaffold was modified with structural motifs identified from a screening campaign with more than 1600 compounds, which were applied against wild-type Her2 and its mutant variant Her2-A775_G776insYVMA. The resulting inhibitors were designed to covalently target a reactive cysteine in the binding site of Her2 and were further optimized by means of structure-based drug design utilizing a set of obtained complex crystal structures. In addition, the analysis of binding kinetics and absorption, distribution, metabolism, and excretion parameters as well as mass spectrometry experiments and western blot analysis substantiated our approach.

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

A pharmaceutical formulation comprising the compound of formula

Synthesis and cytotoxic activity of 2,5-disubstituted pyrimido[5,4-c] quinoline derivatives

A series of 2,5-disubstituted pyrimido[5,4-c]quinoline derivatives were synthesized and their cytotoxic activity against H460, HT-29 and MDA-MB-231 cell lines was evaluated in vitro. It was found that most of the tested compounds especially compound 17, s